摘要
目的分析安罗替尼三线及以上治疗中晚期非小细胞肺癌(NSCLC)的疗效及其影响因素。方法选取2018年6月至2019年5月绍兴第二医院医共体总院收治的中晚期NSCLC患者66例。所有患者均早餐前口服盐酸安罗替尼胶囊治疗,12 mg/次,1次/d,连续服药2周,停药1周,21 d为1个周期。按照实体肿瘤疗效评价标准(RECIST 1.1),统计其客观缓解率(ORR)、疾病控制率(DCR)和无进展生存期(PFS)。比较不同临床特征患者ORR、DCR和PFS。Cox比例风险模型分析影响中晚期NSCLC患者中位PFS的因素。评价药物不良反应。结果66例中晚期NSCLC患者中,部分缓解5例(7.6%),疾病稳定29例(43.9%),疾病进展32例(48.5%),ORR 5例(7.6%),DCR 34例(51.5%)。无脑转移患者DCR高于有脑转移患者,差异有统计学意义(P<0.05)。66例中晚期NSCLC患者中位PFS为3.6个月。鳞癌、肿瘤分期IV期、三线以上治疗、美国东部肿瘤协作组(ECOG)评分2~3分患者中位PFS分别低于腺癌、肿瘤分期ⅢB期、三线治疗、ECOG评分0~1分,差异均有统计学意义(均P<0.05)。Cox比例风险模型显示肿瘤分期、ECOG评分是影响中晚期NSCLC患者中位PFS的因素(均P<0.05)。安罗替尼治疗过程中主要为1~2级的不良反应,对症治疗后症状改善。结论安罗替尼用于三线及以上治疗中晚期NSCLC具有较好的近期疗效及生存获益,对ECOG评分低、肿瘤分期早的患者治疗效果较好,不良反应可耐受,安全性高。
Objective To evaluate the efficacy of anlotinib as third-line treatment and above for patients with advanced non-small cell lung cancer(NSCLC).Methods Sixty-six patients with advanced NSCLC admitted in General Hospital of Medical Community of Shaoxing Second Hospital from June 2018 to May 2019 were included in analysis.Patients were treated with anlotinib hydrochloride capsules(12 mg q.d)for 2 weeks with 3 weeks as a cycle.According to the solid tumor efficacy evaluation standard(RECIST 1.1),objective response rate(ORR),disease control rate(DCR),and progression-free survival(PFS)were evaluate drug reactions were documented.Results Among 66 patients with advanced NSCLC,PR(partial response)accounted for 7.6%(5/66),stable disease accounted for 43.9%(29/66),and progression of disease accounted for 48.5%(32/66)with the ORR of 7.6%(5/66)and DCR of 51.5%(34/66).The DCR of patients with no brain metastases was significantly higher than that of patients with brain metastases(P<0.05).The median PFS was 3.6 months.The median PFS of patients with squamous cell carcinoma,stage IV tumor,third-line treatment or above,and the Eastern Cooperative Oncology Group(ECOG)score 2~3 were lower than that with adenocarcinoma,tumor stage IIIB,third-line treatment,and ECOG score 0~1(all P<0.05).Multivariate Cox prognostic analysis showed that ECOG score and staging were independent predictors of the efficiency of advanced NSCLC(both P<0.05).The main adverse reactions were grade 1~2,which were improved after symptomatic treatment.Conclusion Anlotinib has good short-term efficacy and survival benefits in the treatment of advanced NSCLC in the third-line and above.It is effective in treating patients with low ECOG scores and early stage,with tolerable adverse reactions and high safety.
作者
陈海峰
CHEN Haifeng(Department of Oncology,General Hospital of Medical Community of Shaoxing Second Hospital,Shaoxing 312000,China)
出处
《浙江医学》
CAS
2020年第14期1524-1528,共5页
Zhejiang Medical Journal
关键词
安罗替尼
非小细胞肺癌
三线及以上
中晚期
疗效
影响因素
安全性
Anlotinib
Non-small cell lung cancer
Third-line and above
Advanced
Efficacy
Influencing factors
Safety
